In a nutshell
This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma.
This study concluded that ibrutinib was associated with a higher risk of infections in these patients.
B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of infection. This is due to immune defects associated with cancer. Ibrutinib (Imbruvica) is a targeted therapy used in the treatment of NHL. It was unknown what the risk of infection is in patients with B-cell malignancies treated with ibrutinib.
Methods & findings
This study analyzed results from 7 studies that involved a total of 2167 patients. These studies compared ibrutinib to other agents for B-cell malignancy treatment. Patients were treated for a duration of 9.4 months to 38.7 months.
Ibrutinib was associated with an increased risk of infection in patients with B-cell malignancies (46%) compared to other treatments (37%). Ibrutinib was associated with a 34% higher risk of infections of any severity and a 35% higher risk of serious and life-threatening infections.
There was no significant difference in the risk of pneumonia and upper respiratory tract infection between groups.
The bottom line
This study concluded that ibrutinib was associated with a higher risk of infections in patients with B-cell malignancies.
The fine print
The studies analyzed had different protocols. Patients received ibrutinib as frontline therapy or for relapsed/unresponsive disease. The risk of infection may be different between these categories of patients. Further studies are needed.
Published By :
Clinical lymphoma, myeloma & leukemia
Feb 01, 2020